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Haemoglobin, oxygen carriers and perioperative organ perfusion
Abstract
Under normal conditions, only 20-30% of the delivered oxygen is metabolised. In normovolaemic
anaemia, the organism reacts with increases in cardiac output and oxygen extraction. Once these
mechanisms are exceeded, allogeneic blood transfusions may be administered. However, such
transfusions are associated with serious adverse effects and alternatives such as artificial oxygen carriers
are being sought. The main groups of artificial oxygen carriers are extracellular haemoglobin solutions
and perfluorocarbons. Preparations undergoing experimental and clinical assessment include Human
Polymerized Haemoglobin (Polyheme), Polymerized Bovine Haemoglobin-based Oxygen Carrier
(HBOC-201, Hemopure), Haemoglobin Raffimer (HemoLink), Diaspirin Cross-linked Haemoglobin
(HemAssist), Human Recombinant Haemoglobin (rHb), Enzyme Cross-linked Poly-haemoglobin,
Maleimide-activated Polyethylene-glycol Modified Haemoglobin (MP4, Hemospan), Zero-linked
Haemoglobin (ZL-HbBv) and Recombinant Hybrid of Human-alpha-chains and Bovine-beta-chains and
Perflubron (Oxygent). Research into some of these compounds has been discontinued, while others have
advanced into clinical phase III trials, but none has achieved market approval for Europe, US or Canada
so far.
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Abstract 
Under normal conditions, only 20-30% of the delivered oxygen is metabolized. In 
normovolaemic anaemia the organism reacts with increases in cardiac output and 
oxygen extraction. Once these mechanisms are exceeded, allogeneic blood 
transfusions may be administrated. However, such transfusions are associated with 
serious adverse effects and alternatives such as artificial oxygen carriers are being 
sought.  
Main groups of artificial oxygen carriers are extracellular haemoglobin solution and 
perfluorocarbons. Preparations undergoing experimental and clinical assessment 
include Human Polymerized Haemoglobin (Polyheme®), Polymerized Bovine 
Haemoglobin-based Oxygen Carrier (HBOC-201, Hemopure®), Haemoglobin 
Raffimer (HemoLink®), Diaspirin Cross-linked Haemoglobin (HemAssist®), Human 
Recombinant Haemoglobin (rHb), Enzyme Cross-linked Poly-haemoglobin, 
Maleimide-activated Polyethylene-glycol Modified Haemoglobin (MP4, Hemospan®), 
Zero-linked Haemoglobin (ZL-HbBv), Recombinant Hybrid of Human-α-chains and 
Bovine-β-chains and Perflubron (OxygentTM). Research into some of these 
compounds has been discontinued others have advanced into clinical phase III trials, 
but none has achieved market approval for Europe, US or Canada so far. 
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Physiology of the oxygen delivery 
The main function of erythrocytes is the transport of oxygen (O2) from the lungs to the 
different organs and the peripheral tissues. Normally, about 98 % of O2 is bound to 
haemoglobin (Hb), the rest is physically dissolved in the plasma. A greater proportion 
of dissolved O2 can be reached with a higher inspiratory fraction of O2 (FiO2), which 
may be useful in acute anaemia. 
 
O2 delivery (DO2) is the product of cardiac output (CO) and arterial O2 content 
(CaO2). 
 
DO 2 = CO ● CaO2
 
CaO2 is the sum of O2 bound to Hb and O2 dissolved in the plasma. Normal Hb binds 
1.34 ml O2 per g of Hb at 100% of Hb saturation (SaO2). O2 solubility in relation to its 
arterial partial pressure (PaO2) is 0.0031 ml/mmHg●dl at 37°C.  
Thus, CaO2 is: 
 
CaO2 = (SaO2 ● 1.34 ● Hb) + (0.0031 ● PaO2) 
 
In analogy, mixed-venous (pulmonary artery) O2 content (CvO2) is:  
 
CvO2 = (SvO2 ● 1.34 ● Hb) + (0.0031 ● PvO2) 
 
Total O2 consumption (VO2) is the product of CO and the arterio-venous difference in 
O2 content (AVDO2).  
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 VO2 = CO ● AVDO2  
 
If DO2 and VO2 are known, O2 extraction (EO2) can be calculated as: 
EO2 = VO2/DO2
Under normal circumstances, EO2 is approximately 20 to 30%. This means that there 
is a physiologic reserve. Should DO2 decrease can VO2 be maintained by increasing 
EO2. However, if DO2 continues to decrease, EO2 continues to rise until reaching a 
point where the needed VO2 cannot be maintained anymore – VO2 turns dependent 
of DO2 and starts to decrease with any further reduction in DO2. The DO2, at which 
VO2 starts to decrease, is called critical DO2 (DO2crit). At DO2crit the metabolism 
starts turning anaerobic and as a consequence, the serum lactate starts to increase 
resulting in metabolic acidosis.  
 
Reaction to acute anaemia 
During acute blood loss replaced by crystalloids and colloids, Hb falls and the 
physiological reaction is an increase in CO, an increase in EO2 and right shift of the 
Hb dissociation curve [1]. Decrease in blood viscosity and sympathetic stimulation 
result in an increase in stroke volume [2-4]. Interestingly, a stroke volume increase 
due to anaemia has been observed even under treatment with beta-blockers [5].  
 
In addition, blood flow is redirected to favour the vital organs (brain, heart). This 
autoregulation, varying regionally according to local functional and metabolic activity, 
is thought to be due to several factors including myogenic vascular reaction to 
variations in transmural pressure, endothelial vasoconstrictory or vasodilatatory 
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alterations, vasoregulatory release of neurotransmitters and adjustments of DO2 to 
O2 demand under influence of metabolic mediators [6]. Recruitment of capillaries 
allows for better oxygenation of peripheral tissues. Finally, anaemia stimulated 
increase in erythrocyte 2,3-diphosphoglycerat shifts the Hb dissociation curve to the 
right, allowing for easier off-loading of Hb-bound O2 [7]. Increase of PaO2 has been 
observed under acute normovolemic anaemia (ANH). This could be due to increased 
CO with better pulmonary flow, decreased blood viscosity, better ventilation-perfusion 
relation and possibly pulmonary vasodilatation due to nitric oxide [8-11].  
 
Anaemia tolerance 
There is increasing evidence that much lower Hb concentrations can be tolerated 
than previously admitted. In Jehovah Witnesses, where any red blood cells 
transfusion is usually refused for religious reasons, the most deaths exclusively due 
to anaemia have occurred with Hb significantly below 5 g/dl [12]. Also healthy 
volunteers tolerate a Hb concentrations below 5 g/dl [13]. Case reports mention 
survivals with Hb concentration of only 1.1 g/dl [14].  
 
Cardiac disease 
In patients with cardiac disease, the situation is different. EO2 in the heart is high 
under normal conditions already, with relatively little reserve in case of increased 
metabolic demand. Anaemia thus is mainly compensated by increased coronary flow. 
Therefore, the heart is particularly at risk of inadequate DO2. However, even patients 
with coronary heart disease tolerate moderate normovolaemic anaemia well. [15, 16].  
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ANH to a Hb of 9.3±1.0 g/dl has been tolerated without cardiac ischemia signs such 
as ECG alterations, haemodynamic instability or wall motion abnormality [9, 10]. ANH 
to a haematocrit (Hk) of 28 % had a cardio-protective effect in patients undergoing 
coronary artery bypass graft (CABG) surgery, resulting in less myocardial lesions, 
less arrhythmias and lower need in inotropic support [17, 18]. A large analysis of over 
24’000 patients with acute coronary syndrome has shown a worse outcome in those 
who were transfused with Hk over 25 %. However, Hk was not an endpoint of this 
study and several issues such as transfusion decisions have not been specifically 
addressed [19]. An evaluation of Hk and its influence on the outcome in patients 
undergoing CABG surgery has shown that anaemic patients often had other risk 
factors such as diabetes or congestive heart failure. The only independent factor 
leading to higher mortality found, was a Hk lower than 14 % during the extracorporeal 
circulation[16]. A comparison of patients with cardiac disease including coronary 
artery disease in intensive care units showed no difference in outcome between 
groups transfused at a Hb <7 g/dl vs. a Hb < 10 g/dl [20, 21].  
 
It appears that it is currently difficult to determine one specific Hb value as a universal 
transfusion trigger in patients with coronary artery disease. The decision should 
incorporate the degree of the coronary disease, age and associated pathologies. 
Nevertheless a Hb of 8 g/dl is frequently cited as a Hb based thansfusion trigger in 
patients with stable coronary artery disease [22]. 
 
ANH in valvular heart disease has been less frequently investigated. ANH to a Hb of 
10 g/dl has been well tolerated in mitral insufficiency [23]. Also in severe aortic 
stenosis, haemodilution to a Hk of 28% is well tolerated and accompanied by a CO 
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increase; moreover, it enabled a supplemental cardiac protection with reduced 
myocardial injuries as heralded by an improved haemodynamical stability, lower 
need for inotropic support and reduced release of myocardial enzymes [24, 25].  
 
Intuitively, an increase of CO due to haemodilution would be expected being limited 
by pre-existing cardiac contractile dysfunction. Nevertheless, the compensatory 
mechanisms were independent of left ventricular ejection fraction (LVEF) in the range 
of 26 % to 83 % [10]. However, there was only a limited number of patients with a 
LVEF less than 40 % included [10]. 
 
Elderly patients 
Also elderly patients with and without coronary heart disease aged up to 88 years, 
tolerated ANH well and the compensation mechanisms to ANH were not modified by 
age itself [7, 10]. However, only a limited number of patients were older than 80 
years. Therefore, any extrapolation to patients older than 80 years is fraught with 
difficulties.  
 
Central nervous system 
Experimental ANH from Hb 14.0±1.3 g/dl to Hb 6.0±0.2 g/dl in healthy volunteers 
resulted in impairment of cognitive functions and further dilution to Hb 5.1±.0.2 g/dl 
compromised memory whereas such alterations have not been observed at a Hb of 
7.2±0.2 g/dl and were reversed after transfusion to this Hb. Similarly, alterations of 
neurocognitive functions due to ANH from Hb 12.7±1.0 g/dl to Hb 5.7±0.3 g/dl have 
been reversed by the administration of 100 % O2 increasing PaO2 from 100 to 400 
Haemoglobin, oxygen carriers and perioperative organ perfusion (RK, DRS 2007) 
 
7
mmHg, which corresponds in terms of CaO2 to Hb rise of approximately 3 g/dl [26, 
27].    
 
Transfusion of red blood cells 
Red blood cells transfusion (RBCT) is associated with risk and side effects. The most 
frequent untoward effects are acute and delayed haemolytic reactions and 
alloimmunisation. Infectious risks include transmission of viral diseases (Human 
Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C Virus, possibly other types of 
hepatitis), bacterial diseases (contamination of the red blood cell conserve during 
handling), parasites (malaria) and recently prions (new variant Creutzfeld-Jakob-
Disease) [28-31].  
 
An additional immunological complication is transfusion related acute lung injury 
(TRALI). TRALI is an acute respiratory distress due to bilateral non cardiac 
pulmonary oedema appearing within 6 hours after transfusion often necessitating 
mechanical ventilation [32-34]. Mortality is estimated between 3% and 67% [34-36]. 
Since its diagnostic is made by exclusion of other causes due to absence of any 
specific marker, its frequency may be underestimated. 
 
Still incompletely understood immunological side effect of RBCT is induction of 
immunosuppression, with risk of increased incidence of infections and neoplastic 
diseases [37-41] . 
 
For these reasons, RBCT should be avoided as far as possible and alternatives to 
RBCT should be considered in case of blood loss.  
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 The aim of RBCT is to increase the tissue oxygenation, not to correct a Hb value or 
even to treat hypovolaemia. RBCT which results in increased DO2 but does not 
increase VO2 is indeed a sheer treatment of vascular filling, without other benefits but 
with all transfusion associated risks. The decision of RBCT should be based on 
individual consideration of the patient’s risk to develop any complication due to 
inadequate tissue oxygenation. Signs of inadequate tissue oxygenation or 
“physiologic transfusion triggers” [42], actually considered as transfusion trigger, are 
haemodynamical instability, EO2 greater than 50 %, mixed-venous O2 partial 
pressure (PvO2) under 32 mmHg, VO2 decreased by more than 10 %, and finally 
myocardial ischemia characterized by new ST-segment elevation or depression and 
new wall motion abnormalities in echocardiography [43, 44].  
 
Postoperative Hb below 6,0 g/dl was associated with increased morbidity and 
mortality [45] and it appears that this Hb value per se can justify a RBCT even 
without physiologic signs of inadequate tissue oxygenation in most patients, 
particularly those with coexisting cardiac disease [45-47]. No RBCT is generally 
needed in patients with Hb over 10 g/dl [46]. Between these limits, RBCT should only 
be given to prevent or treat inadequate tissue oxygenation, heralded by apparition of 
above mentioned transfusion triggers. 
 
In order to avoid unnecessary allogenic RBCT, several alternatives should be 
considered: autologous blood donation, acute normovolaemic haemodilution, 
perioperative blood recuperation, pharmacological treatment (erythropoietin, 
antifibrinolytics), careful anaesthesia and surgery techniques, tolerance of low Hb 
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levels, normothermia to enhance coagulation, ventilation with high FiO2, controlled 
hypotension in particular settings, and in future, artificial oxygen carriers. Particular 
attention should be given to maintaining the blood coagulation in order to avoid 
unnecessary blood loss. 
 
Artificial oxygen carriers 
Artificial oxygen carriers are pharmacological substances aiming to improve DO2 
independently of red blood cells. They could become a valuable alternative to RBCT 
in the future, avoiding the actual transfusion risks. However, they only transport O2 
and do not have any other blood capacity, such as coagulation or immunological 
functions. 
 
Ideal artificial O2-carrier would have the following advantages: no need for blood 
group testing, immediate availability in sufficient quantities, no immunological activity, 
no risk of infectious disease transmission, long intravascular half-time and long shelf 
life. They should be available for blood loss substitution, but they could be used also 
for reperfusion of ischemic organs due to vascular strokes, for cardioplegia priming 
and as preservative for transplanted organs. 
 
Two groups are currently under investigation: modified extracellular haemoglobin 
based solutions and perfluorocarbon emulsions. Both are capable of binding O2 but 
their functional characteristics are totally different. Although experimental and clinical 
investigation is far advanced, none of these products has been market approved until 
now. 
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A third group, particulate haemoglobin preparations able to carry other useful 
substances such as enzymes are also studied, but their development is still far from 
any clinical application [48-51].  
 
1. Modified haemoglobin solutions  
Haemoglobin is a tetramer of two α and two β polypeptide chains, bound to an iron-
containing heme group. Extracellular human haemoglobin (α2-β2-tetramers) 
dissociates into α-β-dimers which are nephrotoxic. In order to prevent this, the 
haemoglobin has to be chemically or genetically modified [50].  
 
Modified haemoglobin has similar O2 loading and transport capacity as the native 
blood, with sigmoid dissociation curve [50]. Thus even with relatively low PaO2 a 
sufficient amount of O2 can be transported. Since the modifications of the 
haemoglobin further decrease its affinity for O2, the peripheral O2 unloading is 
facilitated.  
 
Several animal studies have shown the efficacy of modified haemoglobin to transport 
and unload O2; however, important side effects have been observed [3, 52-54]. 
Vasoconstriction with increase of systemic and pulmonary pressures, appears to be 
due to nitric oxide (NO) scavenging, probably by extravasated haemoglobin, 
endothelin release and sensitization of peripheral α-receptors [3, 55-59]. The most 
affected segment appears to be the microcirculation with a reduction of the functional 
capillary density [60]. It has been observed that haemoglobin solutions with different 
O2 affinity caused different degrees of vasoconstrictions [61, 62]. However, the 
hypothesis of autoregulatory vasoconstriction due to relative hyperoxic state caused 
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by better O2 unloading is in contradiction with multiples observation of better tissue 
PO2 during hyperoxic ventilation [63-68].  
 
Iron overload with administration of extracellular haemoglobin could be a concern, 
particularly since this might compromises the immune function – in experimental 
animal models, the mortality has been increased after iron supplementation [69-71]. 
Further frequently observed side effects of haemoglobin based solutions is elevation 
of pancreatic enzymes and bilirubin. Since haemoglobin based solutions are 
coloured substances, they may affect some colorimetric laboratory measurements 
[72]. They do not affect the blood group and rhesus determination [73]. 
 
Different haemoglobin based solutions have been tested: stoma free Hb (“first 
generation”), polymerized Hb (“second generation”), intramolecularly cross-linked Hb 
(“third generation”) and more recently, Hb solutions aiming to reduce vasoconstriction  
(“fourth generation”) [74]. 
 
Stroma-Free Haemoglobin (SFH) 
The idea of substituting haemoglobin as extracellular substance is over 100 years 
old. The early studies showed considerable side effects, most notably renal 
impairment due to vasoconstriction [75-77]. As a consequence, SHF has been 
abandoned as blood substitute. 
 
Human Polymerized Haemoglobin (PolyHeme®) 
Outdated human blood is haemolysed yielding haemoglobin then purified, 
pyridoxylated to decrease the O2 affinity and polymerized with glutaraldehyde [54, 78, 
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79]. Animal experiences and clinical investigation in trauma and emergency surgery 
showed a good tolerance of very low haematocrit if supplemented with Polyheme, 
decreasing the need for RBCT [78, 80, 81]. Interestingly, no serious side effects have 
been observed except an increase in bilirubine and amylase, and particularly no 
hypertension. Another large study on 171 patients with emergency surgery showed 
good survival of those with low haematocrit treated with Polyheme, however the 
comparison with a historic group seemed not to be quite adequate [82] .  
No Biological License Application has been granted by the US Food and Drug 
Administration (FDA) yet. Currently, a randomized phase III trial with PolyHeme® in 
720 patients in the pre-hospital setting is being completed, and results are expected 
later in 2007 [74]. 
 
Polymerized Bovine Haemoglobin-Based O2 Carrier (HBOC-201, Hemopure) 
HBOC-201 is bovine haemoglobin, polymerized by glutaraldehyd-lysin binding within 
the haemoglobin molecule; additional filtration eliminates the non-polymerized 
haemoglobin tetramers [54]. Studies in vascular, orthopaedic and cardiac surgery 
showed substantial reduction of need for allogenic blood with up to 59% of patients 
avoiding RBCT; however, side effects observed with HBOC-201 included 
vasoconstriction, raised amylase and lipase suggesting pancreatic disturbances, 
abdominal pain, dysphagia, nausea, oliguria, late methaemoglobinemia and 
apparition of IgG antiHBOC-201 [83-86]. 
No Biological License Application has been granted by the FDA yet, but HBOC-201 
is approved for clinical use in South Africa. 
 
Haemoglobin Raffimer (HemoLinkTM) 
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O-raffinose cross-links the β-chains forming stable tetramers, and it binds surface 
amino acids resulting in haemoglobin polymerization. In animal studies, similar tissue 
pO2 could be achieved as with RBCT [87]. In patients undergoing cardiac surgery, 
treatment with haemoglobin raffimer allowed a reduction of RBCT as compared 
pentastarch [88-90]. However, common side effects of haemoglobin based solutions 
have been observed, including hypertension, increase in pancreatic enzymes and 
raised bilirubin. HemoLinkTM has actually been abandoned due to cardiac toxicity 
observed during the clinical trials [74]. 
 
Diaspirin cross-linked haemoglobin (HemAssist) 
Cross-linking of the haemoglobin α-subunits with diaspirin prevents the breakdown 
into α-β-dimers and lowers the O2 affinity [91, 92]. In animal models, diaspirin cross-
linked haemoglobin (DCLH) resulted in better wound healing, enhanced hepatic cell 
proliferation and decreased splanchnic bacterial translocation as compared with 
transfusion of autologous blood [93]. DCLH furthermore allowed an extreme 
haemodilution without signs of myocardial ischemia [94]. During clinical trials, use of 
DCLH allowed a significant reduction of RBCT in patients undergoing cardiac and 
non cardiac surgery [95, 96]. However, the administration of DCLH also resulted in 
higher incidence of icterus, pancreatitis and urinary complications. In trauma patients, 
DCLH even caused an increased mortality, possibly by aggravated blood loss due to 
vasoconstriction conditioned hypertension – the studies were terminated prematurely 
[97, 98]. Finally, the development of DCLH has been discontinued. 
 
Human Recombinant Haemoglobin (rHb) 
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Human haemoglobin expressed in Escherichia Coli is stabilized by alteration of 
several of its amino acid sequences [99, 100]. This mutation decreases the O2 affinity 
and virtually eliminates renal toxicity. The vasoconstriction due to NO scavenging 
with systemic and pulmonary hypertension remains a notable side effect of rHb. 
Moreover, an increase in amylase and lipase has been observed, suggesting 
alteration in pancreatic microcirculation [101]. However, further modification of rHb 
(rHb 2.0) allowed to mitigate the vascular response [102, 103]. 
 
Initial animal studies showed promising results: rHb 2.0 proved valuable in 
resuscitation of dogs and rats [101, 104], and allowed a nearly complete blood 
exchange [105]. However, despite these encouraging results, the further 
development of rHb 2.0 has been recently stopped. 
 
Enzyme Cross-Linked Poly-Haemoglobin 
Cross-linking of polymerized haemoglobin with catalase and superoxid-dismutase 
can be useful in case of organ ischemia, to prevent the formation of superoxide from 
accumulated hypoxanthine and newly delivered O2 with resulting free oxygen 
radicals. Protection from reperfusion injury and free radicals scavenging could be 
demonstrated in animal model [106, 107]. Larger animal and clinical investigation 
have to be done before introducing enzyme cross-linked poly-haemoglobin into 
clinical practice.  
 
Maleimide-Activated Polyethylene Glycol Modified Haemoglobin (MP4, 
Hemospan) 
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NO-scavenging seems not to be the sole mechanism leading to vasoconstriction with 
extracellular haemoglobin solutions. Different degrees of vasoconstriction could be 
achieved with differently modified haemoglobins having nevertheless similar NO 
binding [103]. Excessive oxygen unloading may have vasoconstrictive effects, 
particularly on arterioles; consequently, with larger thus less diffusible and less 
extravasating haemoglobin molecules having greater O2 affinity vasoconstriction 
should be reduced [108-110]. 
 
Based on this hypothesis of autoregulatory vasoconstriction in hyperoxic conditions 
[111, 112], a haemoglobin solution with larger molecular size and higher O2 affinity 
has been created by surface conjugation of outdated human blood haemoglobin with 
maleimide-activated polyethylene-glycol in order to decrease hypertensive side effect 
[109]. It has been shown in hamster model that although all cell-free haemoglobin 
solutions scavenge NO, at least a part of the vasoconstrictive effect is due to other 
mechanisms, particularly the molecular size of Hb. The larger molecule of MP4 
resulted in less vasoconstriction then other Hb solutions. Nevertheless, all of them 
resulted in elevation of blood pressure, but while with other Hb solutions this was due 
essentially to arteriolar vasoconstriction, with MP4 the increased blood pressure was 
a consequence of increased cardiac output due to colloidal properties of MP4 [113].  
 
In animal anaemia models, the functional capillary density as an expression of 
vasoconstriction in the microcirculation segment has been preserved by MP4. 
However, RBCT restored tissue oxygenation better than MP4 and the 
haemodynamic response and lactate levels were comparable to treatment with 
hydroxyethyl starch [114-116]. However, the haematocrite achieved during these 
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experiments was still relatively high, 15% and 21%, levels which are usually fairly 
well tolerated even without additional O2 treatment. However, MP4 showed in animal 
model their capacity to sustain oxygenation in extreme haemodilution [114, 117]. 
 
A phase I study on healthy volunteers has shown that MP4 has no clinically 
significant hypertensive and gastrointestinal side effects as have had previous Hb 
solutions [118]. A recent phase II multicenter randomized prospective safety study on 
90 elderly patients undergoing elective hip arthroplasty has confirmed these 
observations. MP4 had no serious adverse effects; the mild elevation of amylase, 
lipase and liver enzyme was not statistically significant but there were a trend to more 
bradycardia events in the MP4 group [119]. However, there is no information about 
preoperative medical treatment, particularly β-blockers. 
 
A phase III study is currently being conducted but the results are not expected before 
2008. 
 
Zero-linked Haemoglobin (ZL-HbBv) 
This recent polymerized bovine-haemoglobin based solution has no intramolecular 
coupling, big molecular size and high O2 affinity [74]. It tends to extravasate less 
[120]. Few data are actually available about ZL-HbBv. 
 
Recombinant Hybrid of Human-α-chains and bovine-β-chains Haemoglobin 
A new haemoglobin molecule, subsequently polymerized through its surface 
sulfhydryl groups, with high O2 affinity, which improved oxygenation in animal brain 
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ischemia model [121]. Once again, little experimental information is available 
concerning this substance so far. 
 
2. Perfluorocarbon emulsions (PFC) 
PFC are carbon-fluorin compounds which are chemically and biologically inert, have 
low viscosity and high gas dissolving capacity (O2, CO2, other gases) [3, 122, 123]. 
They are not miscible with water and have to be conditioned as emulsion with 
droplets of approximately 0,16 µm in order to be biocompatible. This very small size 
could make them interesting not only to substitute for lost blood, but also in situations 
where inadequate tissue oxygenation is due not to anaemia but to extreme vascular 
stenosis impeding the circulation of red blood cells, like a most severe form of 
coronary artery disease or limb ischemia. Unlike Hb solutions, the relation between 
PaO2 and PFC-transported O2 is linear; consequently higher FiO2 is required for 
better O2 transport [49].  
 
Fluosol-DA 
Fluosol-DA has been the first PFC shown to protect the heart during percutaneous 
transluminal coronary angiography (PTCA) and it has been market approved for 
PTCA in 1989 [124-128]. However, it showed no efficacy in the treatment of anaemia 
and has been withdrawn several years later when improvements in balloon 
angioplasty catheters limited its use [123, 129, 130].   
 
Perflubron (OxygentTM) 
After i.v. administration, perflubron (perfluoro-octyl bromide) is absorbed by the 
reticulo-endothelial (RES) system. This absorption determinates its intravascular half-
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time which is dose-dependent, in order of several hours [3, 122, 131, 132]. In RES, 
perflubron droplets are broken down then excreted in the blood again and 
transported to the lungs where they are exhaled, without any known metabolism [3, 
122]. 
 
Animal models of haemodilution have shown the capacity of perflubron to restore 
peripheral tissue oxygenation with amelioration of organ function [63, 133, 134]. This 
is due most likely to favourable off-loading of O2 in hypoxic tissue and to the small 
dimension of perflubron droplet as compared to erythrocytes allowing it to pass even 
very narrow or near totally obstructed vessels. It has been observed that O2 
transported by perflubron is metabolized preferentially to O2 transported by Hb [133].  
In human studies, perflubron allowed to retard or reverse the trigger for RBCT, with 
significantly reduced need for allogeneic blood [131, 132, 135-137]. This effect was 
further accentuated and prolonged with higher doses [135].  
 
Side effects of perflubron are usually mild and without serious clinical consequences. 
Flu-like symptoms with myalgia and light fever have been reported, and decrease of 
approximately 15% in platelet account from third to seventh postoperative day has 
been observed [49]. On the other hand, perflubron has no effect on coagulation tests, 
bleeding time and platelet aggregation [49].  
 
In 2001, a phase III study in cardiac surgery has been suspended, due to reported 
adverse neurologic outcome; however, experts agree that these results were 
probably not due to perflubron itself but more likely to the fast blood harvesting early 
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during the cardiopulmonary bypass [54]. To our knowledge, no major clinical 
development is pursued currently. 
 
3. Other artificial oxygen carriers 
Haemoglobin Containing Liposomes (Neo Red Cells) 
Since several decades, the development of small vesicles (0.1 – 0.3 µm) aims to 
supplement the red cell based O2 transport by artificially created corpuscular carrier. 
Purified haemoglobin is conjugated with phospholipids, cholesterol and α-tocopherol 
[138].  
 
Theoretical advantages of this product include longer intravascular half-time (in the 
order of days), less vasoconstriction and the possibility to include other useful 
substances such as 2,3-DPG or methaemoglobin-reductase to regulate O2 affinity 
and decrease methaemoglobine formation [54, 138, 139], other enzymes such as 
catalase or superoxid-dismutase can be co-encapsulated as well which may prove 
beneficial during reperfusion of hypoxic areas for reducing the reperfusion injury 
[140]. Although the neo red cell technology may enable fascinating combinations of 
heamoglobins and diverse enzymes, a clinical application appears unlikely in the 
near future. 
 
Polymersome Encapsulated Haemoglobin (PEH) 
This recent preparation is bovine haemoglobin encapsulated in polymer vesicles 
(polymersomes) to form PEH. Unlike liposomes, polymersomes can be completely 
covered by polyethylene-glycol (PEG). PEG is a biologically inert polymer, used in 
drug delivery systems and known to be safe for in-vivo administration [48]. It 
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influences the permeability of polymersomes, giving them better mechanical 
resistance with favourable osmotic properties, thus reducing problems with osmotic 
pressure gradients. Further, it enables a better choice of vesicular size. The O2 
affinity has been found comparable to that of human erythrocytes  [48]. PEH is still in 
experimental in-vitro investigation.  
 
Allosteric modifier (RSR13) 
RSR13 (2-[4-[2-[3,5-dimethylphanyl)-2-oxoethyl]phenosy]-2-methyl-propanoic acid 
monosodium salt) has been developed for hyperoxic treatment of tumour in 
combination with radiotherapy. It shifts the haemoglobin dissociation curve to the 
right, decreasing the O2 affinity thus enhancing the O2 unloading [141, 142]. 
However, in animal haemodilution model it has not improve haemodilution tolerance 
or O2 consumption [143]. It is therefore unlikely that this substance could have any 
positive influence on need for RBCT and, no major clinical development is persued to 
our knowledge currently. 
 
Summary 
Increasing experimental and clinical evidence indicates that red blood cells 
transfusion indication should be much more restrictive and considered for every 
patient individually, the only reliable transfusion trigger being apparition of signs of 
inadequate oxygenation.  
During last decades, much research has been done to develop pharmacological 
alternatives to blood transfusion, aiming to avoid its numerous adverse effects and to 
reduce the inherent costs. Different artificial oxygen carriers have been designed, 
most noticeably modified haemoglobin solutions and perfluorocarbon emulsions. 
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Despite major difficulties in the development of clinical artificial O2 carriers, they 
continue to hold great promise in terms of enhanced tissue oxygenation and as a 
substitute for allogeneic blood transfusion. However, their introduction into clinical 
medicine, albeit intensively awaited, may still take a few years. 
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 Practice points 
● In acute anaemia, several compensatory mechanisms maintain oxygen 
consumption: increases of cardiac output and oxygen extraction, right shift of the 
oxygen dissociation curve and redistribution of blood flow to favour vital organs. 
● Anaemia is well tolerated even by patients with co-existing cardiac diseases, 
provided normovolemia is maintained. 
● Blood transfusions are associated with serious and potentially fatal adverse effects 
such as acute transfusion reactions, transmission of infectious diseases, infectious 
complications, transfusion related acute lung injury and circulatory overload. 
● Decision for blood transfusion should be based on individual and physiologic 
transfusion triggers (signs of inadequate oxygenation), not on a general haemoglobin 
level. 
● Alternatives for blood transfusion are restrictive transfusion indication based on 
anemia tolerance, optimized surgical and anaesthesia techniques, coagulation 
monitoring, acute normovolemic dilution, perioperative blood recuperation, 
autologous blood donation and in the future, artificial oxygen carriers. 
● The main groups of artificial oxygen carriers are modified haemoglobin solutions 
and perfluorocarbon emulsions. Although under intensive investigation, none of them 
has currently achieved market approval in Europe, US or Canada. 
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Research Agenda 
● Future research is warranted to find a bed-side monitor assessing tissue 
oxygenation. 
● Artificial oxygen carriers are to be further modified in order to maximize their 
efficacy and to minimize their side effects. 
● Efficacy and safety of artificial oxygen carriers need to be assessed in large scale 
human studies. 
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